PriceTargets.com logo

Principia Biopharma - PRNB Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$100.05 As of 09/28/2020 01:00 AM ET
+0 (0.00%)
Get New Principia Biopharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PRNB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PRNB

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Principia Biopharma in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $100.05.

This chart shows the closing price for PRNB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Principia Biopharma. This rating has held steady since August 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/2/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/31/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/31/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2023

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/19/2020Stifel NicolausDowngradeBuy ➝ Hold$104.00 ➝ $100.00Low
8/18/2020GuggenheimDowngradeBuy ➝ HoldLow
8/18/2020Robert W. BairdBoost TargetOutperform$78.00 ➝ $100.00Low
8/18/2020SVB LeerinkDowngradeOutperform ➝ Market Perform$112.00 ➝ $100.00Low
8/17/2020HC WainwrightDowngradeBuy ➝ Neutral$108.00 ➝ $100.00Low
8/10/2020SVB LeerinkBoost TargetOutperform$80.00 ➝ $112.00High
8/7/2020HC WainwrightBoost TargetBuy$77.00 ➝ $108.00Medium
7/28/2020Evercore ISIInitiated CoverageOutperformLow
7/6/2020GuggenheimInitiated CoverageBuy$100.00Medium
6/23/2020HC WainwrightReiterated RatingBuy$77.00Medium
6/12/2020HC WainwrightReiterated RatingBuy$77.00Low
5/15/2020SVB LeerinkBoost TargetOutperform$72.00 ➝ $80.00Low
5/7/2020HC WainwrightReiterated RatingBuy$77.00Low
4/24/2020Robert W. BairdBoost TargetOutperform$64.00 ➝ $78.00Low
4/24/2020HC WainwrightBoost TargetPositive ➝ Buy$70.00 ➝ $77.00High
4/2/2020Stifel NicolausReiterated RatingBuy$76.00High
3/11/2020Stifel NicolausBoost TargetBuy$66.00 ➝ $76.00High
2/7/2020Wells Fargo & CompanyReiterated RatingBuy$63.00 ➝ $82.00Medium
2/6/2020HC WainwrightBoost TargetBuy$62.00 ➝ $70.00Medium
1/28/2020HC WainwrightReiterated RatingBuy$62.00Low
1/7/2020HC WainwrightReiterated RatingBuy$63.00High
12/31/2019Stifel NicolausReiterated RatingBuyHigh
12/19/2019Stifel NicolausBoost TargetBuy$51.00 ➝ $66.00High
12/9/2019Stifel NicolausReiterated RatingBuyHigh
12/9/2019HC WainwrightReiterated RatingBuy$57.00High
10/21/2019HC WainwrightSet TargetBuy$57.00Medium
10/10/2019Stifel NicolausReiterated RatingBuy$45.00 ➝ $51.00Low
8/11/2019Stifel NicolausReiterated RatingBuy$45.00High
7/30/2019HC WainwrightReiterated RatingBuy$55.00Medium
7/1/2019HC WainwrightInitiated CoverageBuy ➝ Buy$55.00High
4/16/2019Stifel NicolausInitiated CoverageBuy ➝ Buy$45.00Low
3/21/2019SVB LeerinkSet TargetBuy$42.00Low
10/9/2018Robert W. BairdInitiated CoverageOutperformHigh
10/9/2018SVB LeerinkInitiated CoverageOutperform ➝ Outperform$34.00High
10/9/2018Wells Fargo & CompanyInitiated CoverageOutperform ➝ OutperformHigh
10/9/2018Bank of AmericaInitiated CoverageBuy ➝ BuyHigh
(Data available from 3/26/2018 forward)

News Sentiment Rating

0.59 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/28/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/25/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/24/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2023

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Principia Biopharma logo
Principia Biopharma Inc., a late-stage biopharmaceutical company, focuses on developing novel therapies for immunology and oncology. The company is developing PRN1008, an inhibitor that is in Phase III clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial to treat immune thrombocytopenic purpura. It is also developing PRN2246/SAR442168, an inhibitor, which has completed Phase I clinical trial for treating multiple sclerosis (MS) and other central nervous system (CNS) diseases; PRN1371, a drug candidate that is in Phase I clinical trial for the treatment of solid tumors; and oral small molecule inhibitors of the immunoproteasome. The company has a collaboration agreement with Genzyme Corporation to develop relapsing and progressive MS and other diseases of the CNS. Principia Biopharma Inc. was incorporated in 2008 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $100.05
Low: $100.05
High: $100.05

50 Day Range

MA: $100.05
Low: $99.95
High: $100.27

52 Week Range

Now: $100.05
Low: $25.35
High: $101.89

Volume

N/A

Average Volume

729,676 shs

Market Capitalization

$3.32 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.86

Frequently Asked Questions

What sell-side analysts currently cover shares of Principia Biopharma?

The following sell-side analysts have issued research reports on Principia Biopharma in the last twelve months:
View the latest analyst ratings for PRNB.

What is the current price target for Principia Biopharma?

0 Wall Street analysts have set twelve-month price targets for Principia Biopharma in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Principia Biopharma in the next year.
View the latest price targets for PRNB.

What is the current consensus analyst rating for Principia Biopharma?

Principia Biopharma currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for PRNB.

What other companies compete with Principia Biopharma?

Other companies that are similar to Principia Biopharma include Cytokinetics, PTC Therapeutics, Amicus Therapeutics, Maravai LifeSciences and Reata Pharmaceuticals. Learn More about companies similar to Principia Biopharma.

How do I contact Principia Biopharma's investor relations team?

Principia Biopharma's physical mailing address is 220 East Grand Avenue, SOUTH SAN FRANCISCO CA, 94080. The company's listed phone number is 650-416-7700 and its investor relations email address is [email protected] The official website for Principia Biopharma is www.principiabio.com. Learn More about contacing Principia Biopharma investor relations.